探讨重组人血管内皮抑素注射液（商品名Endo）联合抗PD-1治疗80岁及以上老年非小细胞肺癌（NSCLC）患者的疗效和安全性。对181例80岁NSCLC患者进行回顾性分析2019年6月至2024年1月在安徽医科大学附属巢湖医院呼吸与危重症医学科接受治疗的及以上患者。根据纳入标准，纳入至少接受一个周期Endo联合抗PD-1治疗的患者标准。收集临床和病理数据，包括全血细胞计数、肝肾功能、心电图、凝血功能、甲状腺功能、心肌酶和全身成像。记录不良事件并于 2024 年 1 月 25 日进行最终随访。主要终点是无进展生存期 (PFS) 和总生存期 (OS)，安全性作为次要终点。这项研究涉及 14 名老年 NSCLC 患者。超过 80 岁。中位无进展生存期 (mPFS) 为 102 天，中位总生存期 (mOS) 为 311 天。基于治疗周期的亚组分析显示，与短期组（<6 个周期，9 名患者）相比，长期组（≥6 个周期，5 名患者）的 441 天 mPFS 没有显着增加。然而，长期组的mOS显着超过短期组141天，具有统计学意义（P=0.048）。进一步分类显示，与联合维持组（Endo 与Immunol 联合，441 天）相比，单一疗法维持组（Endo 或Immunol）的mPFS 缩短了204 天。单药维持组的mOS（686天）长于联合维持组（311天），但无统计学意义（P=0.710、0.920）。整个治疗过程中，共记录了 77 起不良事件，主要为 1-2 级，没有发生新的治疗相关反应。总体而言，Endo 联合抗 PD-1 的安全性良好且可控。Endo 联合抗 PD-1 可能成为 80 岁及以上 NSCLC 患者的有效治疗选择。版权所有 © 2024 邢高、朱、高、严。

To investigate the efficacy and safety of combining Recombinant Human Endostatin Injection (marketed as Endo) with anti-PD-1 in elderly patients aged 80 and above with non-small cell lung cancer (NSCLC).Retrospective analysis of 181 patients with NSCLC aged 80 and above treated in the Department of Respiratory and Critical Care Medicine at Chaohu Hospital, affiliated with Anhui Medical University, from June 2019 to January 2024. Patients who received at least one cycle of combined Endo with anti-PD-1 were included based on inclusion criteria. Clinical and pathological data were collected, including complete blood count, liver and kidney function, electrocardiogram, coagulation function, thyroid function, cardiac enzymes, and whole-body imaging. Adverse events were recorded with a final follow-up on January 25, 2024. The primary endpoints were progression-free survival (PFS) and overall survival (OS), with safety as a secondary endpoint.This study involved 14 elderly patients with NSCLC aged over 80. Median progression-free survival (mPFS) was 102 days, and median overall survival (mOS) was 311 days. Subgroup analyses based on treatment cycles showed a non-significant 441-day mPFS increase in the long-term group (≥6 cycles, 5 patients) compared to the short-term group (<6 cycles, 9 patients). However, the mOS in the long-term group significantly exceeded the short-term group by 141 days, with statistical significance (P=0.048). Further categorization revealed a 204-day shorter mPFS in the monotherapy maintenance group (Endo or Immunol) compared to the combination maintenance group (Endo combined with Immunol, 441 days). The mOS of the monotherapy maintenance group was longer (686 days) than the combination maintenance group (311 days), but no statistical significance (P= 0.710, 0.920). Throughout the treatment, 77 adverse events were recorded, mainly grade 1-2, with no new treatment-related reactions occurred. Overall, the safety of Endo combined with anti-PD-1 was considered good and manageable.The combination of Endo and anti-PD-1 could be an effective treatment choice for patients with NSCLC aged 80 and above.Copyright © 2024 Xing, Gao, Zhu, Gao and Yan.